Gurnet Point Capital and Patient Square Capital Acquire Radius Health
June 23, 2022
Gurnet Point Capital and Patient Square Capital entered into a definitive agreement to acquire Radius Health in a transaction valued at approximately $890 million, including the assumption of debt. The offer is $10.00 per share in cash plus a $1.00 per share contingent value right (CVR) tied to TYMLOS (abaloparatide) net sales reaching $300 million during a 12-month period prior to December 31, 2025.
- Buyers
- Gurnet Point Capital, Patient Square Capital, OrbiMed Advisors, LLC
- Targets
- Radius Health, Inc.
- Sellers
- Radius Health shareholders
- Industry
- Healthcare Services
- Location
- Massachusetts, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
B-FLEXION Life Sciences to Acquire Remaining 57% of Radius Health from Patient Square and Webster Equity Partners
January 12, 2026
Pharmaceuticals
B-FLEXION Life Sciences has agreed to purchase the remaining 57% interest in Radius Health held by affiliates of Patient Square Capital and Webster Equity Partners. Radius, a specialty biopharmaceutical focused on bone health, had been taken private by B-FLEXION and Patient Square in August 2022. The transaction is expected to close by the end of Q1 2026.
-
Paratek Pharmaceuticals and Radius Health Combination Supported by $1.3B Financing Led by Blackstone Credit & Insurance
March 20, 2026
Pharmaceuticals
Blackstone Credit & Insurance is leading a $1.3 billion financing to support the combination of Paratek Pharmaceuticals and Radius Health, creating a scaled, multi-asset specialty pharmaceutical platform. The combined company is expected to integrate commercial-stage assets and lifecycle/clinical development efforts to expand a diversified portfolio of targeted medicines.
-
Gurnet Point Capital and Novo Holdings Acquire Paratek Pharmaceuticals
September 21, 2023
Pharmaceuticals
Gurnet Point Capital and Novo Holdings completed the acquisition of Paratek Pharmaceuticals for $2.15 per share in cash plus a $0.85 CVR tied to NUZYRA sales, in a transaction valued at approximately $462 million including assumed debt. Oaktree provided $175 million of debt financing; following closing Paratek will be taken private and delisted from Nasdaq as the buyers aim to accelerate commercialization of NUZYRA and expand Paratek's anti-infective portfolio.
-
Patient Square Capital Acquires Paradigm
February 12, 2026
Healthcare Services
Paradigm, a specialty care management organization focused on complex injuries and diagnoses, entered into a definitive agreement to be acquired by Patient Square Capital. The transaction is expected to close in the first half of 2026 and represents the end of Paradigm’s partnership with OMERS Private Equity.
-
Elliott, Patient Square and Veritas Acquire Syneos Health for ~$7.1B
May 10, 2023
Healthcare Services
A consortium of private investment firms—Elliott Investment Management, Patient Square Capital and Veritas Capital—has completed the acquisition of Syneos Health for $43.00 per share, a transaction valued at approximately $7.1 billion including debt. Syneos Health will become a privately held company, with the new owners planning to accelerate its transformation, invest in technology and strengthen its integrated biopharmaceutical services.
-
Patient Square Capital Makes Strategic Investment in CorroHealth; Carlyle to Share Joint Control
October 24, 2024
Healthcare Services
CorroHealth, a Plano-based provider of clinically led revenue cycle management (RCM) and healthcare analytics, has signed definitive agreements for a strategic investment from Patient Square Capital. Current shareholders including Carlyle will remain investors, and Patient Square and Carlyle will share joint control as CorroHealth pursues further organic and inorganic growth.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.